PDCD1 and cancer: Although many checkpoints are suitable targets for cancer immunotherapy, the PD1/PDL1 axis is the most recognized and is already in use for the treatment of both solid (melanoma, non-small cell lung cancer, renal cell carcinoma, etc.)and hematological (Hodgkin’s lymphoma) tumors.